(19)
(11)EP 2 736 520 B1

(12)EUROPEAN PATENT SPECIFICATION

(45)Mention of the grant of the patent:
09.09.2020 Bulletin 2020/37

(21)Application number: 12818073.4

(22)Date of filing:  10.07.2012
(51)International Patent Classification (IPC): 
A61K 8/365(2006.01)
A61K 31/26(2006.01)
A61P 1/02(2006.01)
A61K 8/46(2006.01)
A61K 33/30(2006.01)
A61K 9/08(2006.01)
A61Q 11/00(2006.01)
(86)International application number:
PCT/US2012/046071
(87)International publication number:
WO 2013/015979 (31.01.2013 Gazette  2013/05)

(54)

COMPOSITIONS CONTAINING ZINC SALTS AND ISOTHIOCYANATES FOR REDUCTION OF ORAL VOLATILE SULFUR COMPOUNDS (VSCS)

ZUSAMMENSETZUNGEN MIT ZINKSALZEN UND ISOTHIOCYANATEN ZUR VERRINGERUNG VON ORALEN FLÜCHTIGEN SCHWEFELVERBINDUNGEN (VSCS)

COMPOSITIONS CONTENANT DES SELS DE ZINC ET DES ISOTHIOCYANATES POUR RÉDUCTION DE COMPOSÉS SOUFRÉS VOLATILS ORAUX (VSC)


(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)Priority: 26.07.2011 US 201161511646 P

(43)Date of publication of application:
04.06.2014 Bulletin 2014/23

(73)Proprietor: Wm. Wrigley Jr. Company
Chicago, IL 60611 (US)

(72)Inventors:
  • TIAN, Minmin
    Naperville, Illinois 60564 (US)
  • HANLEY, Bryan
    Norwich NR1 4JA (GB)
  • DODDS, Michael
    La Grange Park, Illinois 60526 (US)

(74)Representative: Dehns 
St. Bride's House 10 Salisbury Square
London EC4Y 8JD
London EC4Y 8JD (GB)


(56)References cited: : 
WO-A1-00/51559
GB-A- 2 436 463
JP-A- 2000 086 414
US-A1- 2003 211 209
US-A1- 2007 053 849
WO-A1-2010/140272
JP-A- H11 246 319
US-A1- 2002 122 843
US-A1- 2006 264 497
  
  • DATABASE GNPD [Online] MINTEL; September 2010 (2010-09), "Multi-nutrient Tablets", XP002739523, Database accession no. 1398454
  • DATABASE GNPD [Online] MINTEL; April 2006 (2006-04), "Healthy Milk Powder for Woman", XP055188634, Database accession no. 524925
  • DATABASE GNPD [Online] MINTEL; August 2003 (2003-08), "Children's chewable multi-vitamin supplement", Database accession no. 10144682
  
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


Description

Background of the Invention



[0001] This invention relates to an efficacious combination of a zinc lactate salt and an isothiocyanate, and more particularly to a chewing gum, pet chew or chew candy containing such combination which exhibits increased oral care effects against volatile sulfur compounds (VSCs).

[0002] Oral malodor or "halitosis" used herein relates to bad breath caused by physiologic (transient or temporary) and/or pathologic conditions. Physiological causes of halitosis include: halitosis caused by deleterious habits, morning breath, and xerostomia (dry mouth). Pathological causes for halitosis include: secondary or oral tissue conditions associated with gingival and periodontal diseases, acute necrotizing ulcerative gingivitis, residual post-operative blood, debris under dental appliances, ulcerative lesions of the oral cavity, coated tongue, xerostomia, salivary gland diseases and Tonsilloliths (tonsil stones).

[0003] Oral malodors are produced mainly due to the breakdown of proteins into individual amino acids, followed by the further breakdown of certain amino acids to produce detectable foul gases. The oral cavity provides a positive growth environment for gram-negative anaerobes that metabolize proteins as an energy source via breakdown of proteinaceous substrates from impacted food particles and sloughed off oral cellular debris. Often, inflammation causes these cells to be shed at a faster rate than the saliva can cleanse. Bacterial action then hydrolyzes the proteins to amino acids; and the amino acids that contain sulfur functional groups, methionine and cysteine, serve as precursors to volatile sulfur compounds (VSCs).

[0004] These gaseous volatile sulfur compounds (VSCs) are responsible for oral malodor, and consist primarily of hydrogen sulfide (H2S), methyl mercaptan (CH3SH) and dimethyl sulfide [(CH3)2S]. For example, amino acids methionine and cysteine are reduced to hydrogen sulfide and methyl mercaptan, respectively, in the presence of sulfhydrase-positive microbes. Methyl mercaptan has been found to be the main component of tongue dorsal surface malodor in patients with periodontal disease, whereas hydrogen sulfide predominates in orally healthy subjects.

[0005] Although bad breath primarily represents a source of embarrassment or annoyance, the VSCs most responsible for halitosis are also potentially damaging to the tissues in the mouth, and can lead to periodontitis (inflammation of the gums and ligaments supporting the teeth). In particular, VSCs have been found to damage the collagen and proteoglycan components in connective tissue by cleaving disulfide bonds. This de-aggregation of the extracellular matrix allows microbes to permeate the oral mucosa. As bacteria further accumulates in pockets that form next to the teeth, periodontal disease progresses, as well as halitosis. If the periodontal disease advances significantly, overall systemic health may be jeopardized; for example, periodontal bacterial by-products can enter the blood stream and may result in heart disease, stroke and under-weight babies at birth.

[0006] For the treatment of oral malodor, the public has increasingly turned to commercially available mouth-freshening products. The market for these products has been growing continuously as sufferers from chronic oral malodor experience personal discomfort and social embarrassment.

[0007] Various compounds such as chlorine dioxide, sodium chlorite, and metal salts such as zinc and copper have been used as VSC neutralizing agents in a variety of oral compositions. Such compounds have been provided and are available today as mouthwashes and rinses for the prevention and/or treatment of oral malodor. In general, many of the oral rinses available today are used for the prevention and/or treatment of oral malodor or halitosis, but for chronic bad breath, many rinses offer little to no help.

[0008] While being effective in fighting oral malodor, compounds such as chlorine dioxide, sodium chlorite, and metal salts such as zinc and copper impart strong, unpleasant flavors and aromas thereby negatively impacting taste and deterring use. Often, mouth rinses incorporating these compounds can also cause some generalized irritations to the oral cavity such as desquamation, ulceration, and inflammation. Moreover, oral compositions incorporating these compounds (other than mouthwashes and rinses) which are retained in the mouth for longer periods of time, such as chewing gums, mints, and lozenges, further enhance irritations to the oral cavity when these compounds are employed.

[0009] Alternatively, isothiocyanates can also act as a reagent to remove both intrinsic and extrinsic VSCs, either by conversion of sulfur groups (SH) into the water soluble dithiocarbamate or by formation of the less volatile disulfide. Unfortunately at certain concentrations, isothiocyanates possess a pungent or irritating odor, and sharp bitter taste. Because of the unpleasant organoleptic attributes, using isothiocyanates in oral compositions is difficult.

[0010] In Record 1398454 of the Mintel database, Multinutrient tablets are disclosed under the trade name Omnium containing a Zn chelate. GB2436463 discloses a breath deodoriser comprising Zn or cetyl pyridinium salts. JP11-243319 discloses an antimicrobial and antifungal agent based on an isocyanate. An animal parade gummies product, Mintel database record 10144682, comprises zinc citrate and broccoli.

[0011] In view of the preceding challenges, there is a continued need to develop an effective treatment for oral malodor caused by physiologic and/or pathologic conditions. Accordingly, the dental community, as well as the general public, are continuously seeking efficacious, commercially available, and organoleptically pleasing oral compositions to reduce various types of bad breath (halitosis), including occasional, chronic, or at specific times of the day.

[0012] Thus, it would be highly advantageous, to have an efficacious, commercially available, and organoleptically pleasant product solution for oral malodor.

SUMMARY OF THE INVENTION



[0013] An oral composition being a chewing gum, pet chew or chewy candy, effective to reduce hydrogen sulfide (H2S), methyl mercaptan (CH3SH) or combinations thereof in the oral cavity, said composition comprising:

0.002 to 2 wt.% of zinc lactate; and

0.001 to 5 wt.% of an isothiocyanate;

wherein the weight ratio of zinc lactate : isothiocyanate is 1:1 to 20:1.

Moreover, methods for reducing volatile sulfur compounds are also provided.

DESCRIPTION OF THE INVENTION



[0014] The present invention relates to an unlikely combination of a zinc lactate salt and isothiocyanate, effective against multiple volatile sulfur compounds (VSCs) present in the oral cavity. Further, the levels of the salt and the isothiocyanates used in combination with one another as described in relation to the invention are lower than each used individually. Accordingly, Applicants invention provides efficacious oral compositions in reducing VSCs, thereby reducing oral malodor.

[0015] As used herein, the term "efficacious" means producing or capable of producing a desired effect. Moreover, "effective amount" refers to the level, amount, serving, or percent which produces or is capable of producing a desired effect. All percentages and ratios used herein are by weight of the total composition and all measurements made are at 25 °C, unless otherwise designated.

[0016] Zinc salts are incompatible with consumer taste acceptance criteria, effective only for short periods of time or not effective at all in reducing certain volatile sulfur compounds, such as methyl mercaptan (CH3SH) when used individually.

[0017] Isothiocyanates are volatile compounds, and are classified as either an oral or nasal irritant, or both. The pungent sensations of isothiocyanates may be sensed throughout the oral mucosal tissues, including the upper respiratory tract.

[0018] As described in more detail below, the invention provides continued breath freshening after consuming or masticating the oral composition. For example, breath freshening benefits will last for at least about 15 minutes, typically for at least about 30 minutes, and preferably for at least about 60 minutes after consumption or mastication of the oral composition. Typically, breath freshening will continue after consumption or mastication for at least about 60 minutes, maintaining a total VSC reduction of at least 50%. As used herein, "total VSC" includes two or more of the following VSCs: hydrogen sulfide (H2S), methyl mercaptan (CH3SH) and dimethyl sulfide [(CH3)2S] in any combination. In other embodiments, breath freshening benefits will continue after 120 minutes with a total VSC reduction of at least 40% and preferably after 180 minutes with a total VSC reduction of at least 20% after consumption or mastication of the oral composition.

[0019] In particular, various embodiments of the invention provide an effective amount of zinc lactate, in combination with an isothiocyanate to inhibit or ameliorate multiple volatile sulfur compounds in an oral composition at a combined concentration of less than 0.50% by weight.

[0020] An oral composition of the present invention can be suitable for application to an oral surface of humans, dogs, cats, or other animals and provides either a cosmetic prophylactic or therapeutic benefit within or derived from the oral cavity. In various embodiments, an oral composition of the invention can be a chewing gum, chewy candy, or pet chew. In certain embodiments, the consuming or masticating of the oral composition may be repeated at regular intervals.

[0021] Applicants have identified suitable, efficacious, and consumer acceptable levels of including both zinc lactate salt and isothiocyanates for use in various oral compositions to reduce multiple VSCs in the oral cavity.

Zinc Salts



[0022] As previously suggested in accordance with various embodiments of the invention, an effective amount of a zinc lactate salt may be used to inhibit volatile sulfur compounds in the oral cavity, thereby reducing oral malodor. Zinc lactate has an average zinc ion content of 23.2%. Under normal circumstances, zinc salts containing a high level of zinc ion perform better than a zinc salt containing low level of zinc ion.

[0023] The use of zinc lactate (molar solubility in water of 0.17 moles/l) is required. Normally, a zinc salt with better water solubility performs better than a zinc salt with poor water solubility.

[0024] Zinc lactate salts have the ability to chelate VSCs present in the oral cavity and form non-volatile metal ion-sulfide complexes, thereby neutralizing oral malodor. However, this ability to neutralize oral malodor is temporary. The salts do not change mouth conditions, and do not exhibit activity against odor producing bacteria present in the oral cavity. Accordingly, oral hygiene products containing zinc salts, such as zinc chloride mouthwashes, are considered by some to be effective for halitosis, but for many, they are not effective and only have temporary effects.

[0025] In general, Applicants have identified that some zinc salts are not effective against all VSCs, such as hydrogen sulfide (H2S), dimethyl sulfide [(CH3)2S], and methyl mercaptan (CH3SH), but instead may only be effective against specific VSCs.

[0026] For evaluation of the efficacy of various zinc salts against specific VSCs, the Applicants established an in vitro method using a headspace gas chromatograph equipped with a sulfur detector. Thus, a total of 200 ppm of CH3SH in 5ml of phosphate buffer solution (PBS) was prepared. The pH was maintained at 7.4. Different amounts of zinc lactate or zinc gluconate were added into the test tube and mixed for 5 minutes at 37 °C. The headspace sample was injected into a gas chromatograph sulfur chemiluminescence detector (GC-SCD). Figure 1 below shows the testing result.



[0027] As shown in Figure 1 above, Applicants identified that both zinc lactate and zinc gluconate were ineffective in reducing the headspace concentration of methyl mercaptan (CH3SH). In fact, Applicants observed that zinc salts tested increased the volatility of CH3SH by 10-40%.

[0028] In another experiment, 5ml of PBS solution containing 1 mg of H2S was prepared via a serial dilution in a 22ml headspace vial for Figure 2 below. Different amounts of zinc salts were added and mixed at 37°C for 5min. The headspace concentration of H2S was analyzed by GC-SCD. Figure 2 shows the testing results.





[0029] As shown in Figure 2 above, Applicants have identified that zinc gluconate, zinc lactate, zinc hydrogen aspartate, and zinc ascorbate reduces the oral malodor produced by hydrogen sulfide (H2S).

[0030] More significantly, zinc lactate reduces H2S at concentrations greater than 0.25mg, and zinc gluconate, zinc hydrogen aspartate, and zinc ascorbate at concentrations greater than 0.5mg in vitro.

[0031] Thus, Applicants surprisingly found that neither zinc lactate nor zinc gluconate reduced the headspace concentration of the volatile sulfur compound methyl mercaptan (CH3SH), which is a more offensive and sensitive odorant compared to hydrogen sulfide (H2S).

[0032] Unfortunately, while being effective against some VSCs, salts of metal cations such as aluminum sulfate and zinc chlorite, zinc lactate, zinc acetate, and the like, are often unpleasant or unpalatable to many consumers. Due to this undesirable effect caused by products containing metal salts, and in consideration of the temporary halitosis neutralization benefits, consumer motivation to purchase and use products containing these ingredients in the treatment of oral malodor is low.

Isothiocyanates



[0033] Isothiocyanates are volatile compounds, and are classified as either an oral or nasal irritant, or both. The pungent sensations of isothiocyanates may be sensed throughout the mucosal tissues of the mouth as well as in the upper respiratory tract.

[0034] Isothiocyanates are bound as precursors in whole vegetables and are released through enzymatic action when the plant materials are ground. Isothiocyanates are biologically active hydrolysis (breakdown) products of glucosinolates. Cruciferous vegetables such as broccoli, cauliflower, kale, turnips, collards, brussel sprouts, cabbage, kohlrabi, rutabaga, Chinese cabbage, and bok choy contain a variety of glucosinolates, each of which forms a different isothiocyanate when hydrolyzed and is illustrated in Figure 3.



[0035] For example, broccoli is a good source of glucoraphanin, the glucosinolate precursor of sulforaphane (SFN), and sinigrin, the glucosinolate precursor of allyl isothiocyanate (AITC). Watercress is a rich source of gluconasturtiin, the precursor of phenethyl isothiocyanate (PEITC), while garden cress is rich in glucotropaeolin, the precursor of benzyl isothiocyanate (BITC). Studies have shown that these compounds are responsible for the unpleasant taste of cruciferous vegetables, raw or cooked.

[0036] Horseradish and mustard share the common family of isothiocyanates as pungent principles. Allyl isothiocyanate (AITC), which occurs in both mustard and horseradish, is the most common member of this family. Brown mustards contain 3-butenyl isothiocyanate. Brassica glucosinolates, otherwise known as mustard oil glycosides, tend to be bitter.

[0037] Natural Isothiocyanates useful in this invention include the following myrosinase-catalyzed glucosinolate compounds from the plant family Brassicaceae: sulforaphane (SFN), allyl isothiocyanate (AITC), phenethyl isothiocyanate (PEITC), benzyl isothiocyanate (BITC), as shown in Figure 3. Preferable natural isothiocyanates useful in this invention are allyl isothiocyanates, also known as mustard oils, and commonly found in horseradish, and wasabi. As described herein, the term "natural" means a chemical compound or substance produced by a living organism and found in nature, which may possess a pharmacological or biological activity for use in pharmaceutical drug discovery and drug design. A product may be considered as "natural" although the product is prepared by total synthesis if the components are substantially identical to a substance found in nature.

[0038] Examples of synthetic or non-natural isothiocyanates include 3-morpholinopropyl isothiocyanate, phenylisothiocyanate, and norbornyl isiocyanate ([endo-2-acetyl-exo-6-isothiocyanatonorbornane, exo-2-acetyl-exo-6-isothiocyanatonorbornane, exo-2-acetyl-exo-5-isthiocyantonorbornane], which can be synthesized from sulforaphane or from commercially available 2-acetyl-5-norbornene).

[0039] Applicants tested a variety of isothiocyanates against the volatile sulfur compound, hydrogen sulfide (H2S).

[0040] A stock solution of H2S was prepared by a serial dilution in PBS buffer (pH 7.4), with a final concentration of 200 ppm. Allyl isothiocyanate, benzyl isothiocyanate, ethyl isothiocyanate and 3-methylthiopropyl isothiocyanate (all from Sigma-Aldrich) were dissolved in pure ethanol to form 1.0% of working solution of each. A total of 5ml PBS buffer containing 200 ppm of H2S in a headspace vial (22ml volume) was mixed with 0.125, 0.25, 0.5 and 1mg of each isothiocyanate compound for 5 min at 37°C, respectively. The headspace sample was injected into the GC-SCD by an automatic sampler for VSC analysis. The reduction of headspace concentration of H2S was calculated by the formula below:

Table 1 - In vitro reduction of hydrogen sulfide (H2S) by allyl isothiocyanate, benzyl isothiocyanate, ethyl isothiocyanate and 3-methylthiopropyl isothiocyanate:
SampleAmountPeak Area% Reduction of headspace concentration
Control 200 ppm 853223827 0%
Allyl isothiocyanate 50 ppm 431713256 49%
  100 ppm 13651581 98.4%
  200 ppm 4266119 99.5%
Benzyl isothiocyanate 25 ppm 491908604 42%
  50 ppm 398519292 53%
Ethylisothiocyanate 50 ppm 963110533 -13%
  100 ppm 726258436 14.9%
  200 ppm 271822727 68%
3-methylthiopropyl 50 ppm 416687277 51%
isothiocyanate 100 ppm 211177117 75%
  200 ppm 46897168 94.5%


[0041] Table 1 above indicates that the isothiocyanates tested aid in reducing hydrogen sulfide (H2S). At 50ppm, benzyl isothiocyanate demonstrated a reduction of H2S of greater than 50%. More significantly, ethylisothiocyanate reduced the headspace of H2S by 68% at 200ppm; 3-methylthiopropyl isothiocyanate reduced the headspace of H2S by 75% at 100ppm, and 94.5% at 200ppm. In particular, allyl isothiocyanate (AITC) showed a strong reduction of H2S (greater than 90% at 100ppm or greater).

[0042] However, to provide the efficacious levels as shown above in an oral composition, this would impart strong, unpleasant tastes, and would not be organoleptically pleasing.

[0043] In view of the results pertaining to allyl isothiocyanate in Table 1, Applicants further evaluated allyl isothiocyanate in vitro for its VSC elimination effect of hydrogen sulfide (H2S). A 20ml headspace vial containing 5ml of PBS solution and 200 ppm of H2S was treated with various concentrations of allyl isothiocyanate, respectively (0.25 - 1.0mg). In a standard experimental protocol, a stock of hydrogen sulfide solutions were prepared by dissolving c.a. 0.10g of sodium sulfide in a total of 10 ml phosphate buffer solution (PBS) (pH 7.4) . It was further diluted in PBS to produce a working solution contained 200 ppm of H2S in buffer.
Table 2 - In vitro reduction of hydrogen sulfide (H2S) by allyl isothiocyanate (AITC)
Allyl isothiocyanateReduction of H2S
0 mg 0.0%
0.25mg 49.0%
0.5mg 98.4%
1mg 99.5%


[0044] Table 2 indicates that allyl isothiocyanate (AITC) reduces oral malodor associated with hydrogen sulfide (H2S) at concentrations greater than 0.25mg (or 50 ppm) in vitro.

[0045] In view of the preceding efficacy identified in vitro (Tables 1 & 2), allyl isothiocyanate (AITC) was further evaluated for in vivo breath freshening effects.

[0046] Chewing gum containing 100 ppm of allyl isothiocyanate (AITC) was prepared in the laboratory, and was rolled, sheeted, and cut into sticks with a weight average of 2.7g.

[0047] A randomized, double-blind clinical study was conducted for evaluation of chewing gum containing allyl isothiocyanate (AITC). A total of 15 subjects met inclusion and exclusion criteria were recruited and completed the study. Subjects were instructed to refrain from oral hygiene, eating and drinking to the testing site. Each subject exhaled his/her breath to a gas chromatograph to analyze for baseline (before treatment, t=0) VSC. Subjects then chewed 1 dose of experimental gum (or control gum) for 12 minutes. Subject exhaled his/her breath to the gas chromatograph immediately after chew, and 60, 120, and 180 minutes. Each test was repeated twice. There were at least two days between treatments.
Table 3 - In vivo reduction of H2S using chewing gum containing 100 ppm of allyl isothiocyanate (AITC)
 Gum-base1(no AITC, flavor, or sweeteners)Control gum (no AITC)Experimental (100 ppm AITC)
Baseline 0% 0% 0%
Immediate after chew 1% 39% 60% †
60 min -10% 10% 28%
120 min -35% -18% 23%
180 min -39% -20% 2%
1. Results from previous study
† Statistical significant compared with baseline
* Statistically significant compared with control gum


[0048] Table 3 shows that chewing gum containing 100 ppm AITC-gum reduces oral malodor associated with hydrogen sulfide (H2S), over the control gum and baseline (pre-treatment, t=0); the results were significant (p>0.05) when compared with baseline results immediately after chewing. Further, when compared to the in vitro hydrogen sulfide (H2S) testing reflected in Table 2, AITC appears less efficacious when applied to chewing gum compositions.
Table 4 - In vivo reduction of CH3SH using chewing gum containing 100 ppm of allyl isothiocyanate (AITC)
 Gumbase1(no AITC, flavor, or sweeteners)Control gum ( No AITC)Experiemental gum (100 ppm AITC)
Baseline 0% 0% 0%
Immediate after chew 8% 56%† 73% †
60 min -24% 3% 46% †
120 min -110% --64% 32%
180 min -90% --73% 12%
1. Results from previous study
† Statistical significant compared with baseline
* Statistically significant compared with control gum


[0049] The date of Table 4 above shows that the experimental AITC-gum reduces CH3SH associated with oral malodor, over the control gum and baseline (pre-treatment, t=0); the results were significant (p>0.05) when compared with both the control gum and baseline immediately after chewing, and after 60 min when compared to baseline result.

[0050] In light of the decreased efficacy of AITC found in vivo when compared to the in vitro results, Applicants tested allyl isothiocyanate for its ability to release from chewing gum. One piece of gum (piece weight: 2.7g) containing 0.27mg of allyl isothiocyanate were chewed for 20 minutes and the residual gum cud analyzed by gas chromatography. Results were compared with extraction of unchewed gum from which recovery was 48.5%. The release of allyl isothiocyanate from the gum was found to be 69.6% after 20 minutes of chewing.

[0051] While isothiocyanates such as allyl isothiocyanate show ability in reducing VSCs (such as H2S), those skilled in the art recognize that isothiocyanates impart pungent aroma, spicy, bitter taste, and are irritating to both the oral and the mucous membranes, even when consumed at low levels. The levels shown to be efficacious would impart unpleasant taste and other negative organoleptic properties to a consumer. It is understood that the effective concentrations of isothiocyanates demonstrated is constrained by the need to provide oral malodor reduction without adversely affecting the appearance, taste, color or texture of various oral compositions.

Combination of zinc salts and isothiocyanates



[0052] In accordance with the present invention, combinations of metal salts and isothiocyanates have been found effective against multiple volatile sulfur compounds (VSCs) present in the oral cavity. Further, the combination and levels described herein are lower than if used individually, providing consumer acceptable and efficacious oral compositions in reducing VSCs, thereby reducing oral malodor.

[0053] As established above, when used individually, zinc salts or isothiocyanates may be effective for short periods of time or not effective at all in reducing certain volatile sulfur compounds (such as methyl mercaptan (CH3SH)). Applicants combination of both compounds provide for efficacious amelioration of multiple VSCs for extended periods of time, even post-mastication or consumption. Moreover, the combination of metal salts and isothiocyanates yield an organoleptically pleasing taste that is acceptable by consumers compared to when each of the compounds are used individually, at higher levels.

[0054] Compositions useful to the invention comprise a zinc lactate salt and a compound extracted from mustard oil, such as such allyl isothiocyanate, ("AITC") or a synthetic or semi-synthetic equivalent of such a component or compound thereof. Typically, AITC may be extracts of mustard oils.

[0055] The relative combination of the zinc lactate salt and isothiocyanate to one another provide the desire effects of Applicants invention. More particularly, an effective concentration of zinc lactate and allyl isothiocyanate in an oral composition of this invention depends not only upon the relative concentration at which enhancement of activity against volatile sulfur compounds is achieved, but also when a consumer acceptable taste is provided. In an aspect of the invention, an enhanced weight ratio of zinc lactate salt/ isothiocyanate in an oral composition is at least at least 1:1. This weight ratio may range up to 20:1 or above, preferably up to 10:1.

[0056] In an embodiment, the ratio of zinc lactate salt to isothiocyanate is between 1:1 to about 20:1 wherein the isothiocyanate is allyl isothiocyanate.

[0057] In other embodiments of the invention, the zinc lactate salt is present in the oral composition in an amount of about 0.002 to about 0.50 wt.%. Such a concentration is dependent upon the concentration of the isothiocyanate employed for enhanced results against volatile sulfur compounds (VSCs). In one embodiment, the zinc lactate salt is present in the oral composition in an amount of about 0.001 to about 1 wt.%. In other embodiments, the zinc lactate salt is present at less than 0.50 wt.%, for example the zinc lactate salt is present at a concentration of in an amount of about 0.01 to about 0.25 wt.%. In one preferred embodiment, zinc lactate is present in the oral composition at a concentration of about 0.10 wt.%. Overall, the concentration of zinc lactate salt is below a level which produces an objectionable taste.

[0058] Still further, the isothiocyanate is present in the oral composition in an amount of about 0.001 % to about 1 wt.%. In other embodiments, the isothiocyanate present at less than 1 %. In one preferred embodiment, the allyl isothiocyanate is present in the oral composition at a concentration of about 0.01 wt.%. Allyl isothiocyanate may be determined by a gas chromatograph-mass spectrophotometer (GC-MS). The isothiocyanate may be natural or non-natural, including but not limiting to sulforaphane (SFN), allyl isothiocyanate (AITC), phenethyl isothiocyanate (PEITC), benzyl isothiocyanate (BITC), 3-morpholinopropyl isothiocyanate, phenylisothiocyanate, and norbornyl isiocyanate ([endo-2-acetyl-exo-6-isothiocyanatonorbornane, exo-2-acetyl-exo-6-isothiocyanatonorbornane, exo-2-acetyl-exo-5-isthiocyantonorbornane], which can be synthesized from sulforaphane or from commercially available 2-acetyl-5-norbornene), alone or in any combination.

[0059] Oral compositions useful in this invention contain a VSC reducing effective amount of a zinc lactate salt and an isothiocyanate combined with a suitable carrier. A suitable carrier typically is a food-acceptable or food contact acceptable material in which the zinc lactate salt and isothiocyanate used in the invention may be incorporated or dispersed without adverse effect. A typical suitable carrier is a watersoluble solid or chewable solid such as a confectionery composition. Another suitable carrier is a dentifrice such as a past or powder. Other suitable carriers for cats, dogs and other animals include but are not limited to chews.

[0060] The term "confectionery composition" as used herein includes chewing gums,. Saliva dissolves the chewable gum product, and promotes prolonged contact with oral surfaces so that the delivery of the VSC reducing agents in a chewing gum form ensures that an adequate dosage of the active ingredients are delivered to the oral surface when the product is used.

[0061] In an embodiment, an oral composition is a chewing gum composition which is suitable for chewing and which comprises 2% or greater, by weight of the composition, of elastomer. In general, chewing gum compositions are chewed or masticated by consumers, the process by which food is mashed and crushed by teeth. Such chewing gum compositions can take a variety of shapes and forms, for example, a pellet, a gumball, a square, a stick, etc., and may be coated by a variety of materials including but not limiting to sugars, polyols, chocolates, syrups, films, and the like, alone or in any combination. Natural or artificial colors and combinations thereof, high intensity sweeteners and flavors may also be added to the coating solution. For pellet or coated chewing gums, zinc salts may be incorporated in a coating or in a center.

[0062] A chewing gum useful to the invention is a sugarless chewing gum containing a zinc lactate salt and an isothiocyanate to reduce VSCs. Chewing gum formulations typically contain, in addition to, a chewing gum base, one or more plasticizing agents, at least one sweetening agent and at least one flavoring agent.

[0063] In accordance with an embodiment, a chewing gum is provided containing zinc lactate from about 0.002% to about 2% by weight, and allyl isothiocyanate from of 0.001 % to about 5% by weight, wherein the chewing gum provided a reduction in multiple VSCs up to 180 minutes after chewing.

[0064] In an aspect of the invention, a chewing gum composition is provided wherein the zinc lactate salt is at a concentration of about 0.10% by weight, and the isothiocyanate is at a concentration of about 0.01 % by weight. The isothiocyanate provided may comprise multiple isothiocyanates, natural or non-natural, and combinations thereof. The chewing gum is masticated for at least 5minutes, for at least 10 minutes, or for at least 15 minutes. Total VSC reduction occurs immediately after post-mastication, or for at least 30 minutes, 60 minutes, typically for at least 90 minutes, and preferably for at least 120 minutes.

[0065] In an embodiment, the allyl isothiocyanate has at least 50% release from a chewing gum into the oral cavity of the user.

[0066] In another embodiment, a hard sugarfree candy is provided, containing less than 0.50% by weight zinc lactate salt, and less than 1 % by weight isothiocyanate.

[0067] While not limiting to theories by which the present invention is bound, it is generally believed that a minimum enhanced effective anti-volatile sulfur compound level (VSC) of zinc lactate salt is between about 100 µg/mL (100 mg/kg or parts per million (ppm)) to about 2500 µg/mL (2500 ppm) and the isothiocyanate concentration is between 10 µg/mL (10ppm) to about 1000µg/mL (1000 ppm) against VSCs in an oral composition.

[0068] In an embodiment, the level of allyl isothiocyanate is less than 50ppm in an oral composition.

[0069] In a preferred embodiment, an effective enhanced breath freshening level of zinc lactate against VSCs is between 100 µg/mL to about 2000 µg/mL and the isothiocyanate is selected from the group consisting of allyl isothiocyanate, benzyl isothiocyanate, phenethyl isothiocyanate, and sulforphane, wherein the level of isothiocyanate is between 10 µg/mL to about 500 µg/mL.

[0070] In an aspect of the invention an oral suspension is provided wherein a zinc salt is provided at about 1250 µg/mL, and the non-natural isothiocyanate is provided at about 1000 µg/mL.

I. DATA


a. Combination of Zinc Lactate and allyl isothiocyanate (AITC) against multiple VSCs: H2S and CH3SH



[0071] Method: A mixture of hydrogen sulfide (H2S) and methyl mercaptan (CH3SH) was prepared by mixing 5 parts of H2S and 1 part of CH3SH in an aqueous phosphate buffer solution (PBS) at pH 7.4. The final concentrations of H2S and CH3SH in solution were a 200 and 40 ppm, respectively. The final amount of VSC was 1.2mg in the test vial. Although the headspace concentrations of H2S and CH3SH were well above the level found in a typical foul mouth air (200-500 parts per billion), the total amount of VSC was close to the amount presented in oral cavity. Subsequently, 5ml of the VSC mixture was kept in a 22ml tight screw cap headspace vial at 37 °C for 5 min. The headspace sample was injected into a GC column with an SCD detector. Figure 4 below shows the testing result (control). The large peak area of CH3SH reflects its volatility in the headspace compared with H2S.

[0072] Separately, 1mg of zinc lactate, or 1mg of allyl isothiocyanate (AITC), or combination of 1mg Zinc lactate and 1mg of AITC were added to each of headspace vial containing 5ml VSC mixture and equilibrated at 37ºC for 5 min. Each headspace sample was injected into a GC column by a Combi-Pal autosampler. The amount of sulfur was analyzed by an Agilent SCD-355 chemoluminescent sulfide detector.



[0073] Figure 4 demonstrates allyl isothiocyanate (AITC) and zinc lactate (ZnL or ZL) exhibit an enhanced effect on multiple VSCs (H2S and CH3SH); 1mg of AITC eliminates 98% of H2S and 78% of CH3SH; 1mg of ZL eliminates 98% of H2S, 0% of CH3SH.

b. Expert Panelist Evaluation of Taste & Sensory of AITC-ZL Gum



[0074] To evaluate the sensory and taste acceptance of the AITC-Zinc gum, an ESA (Expert Sensory Analysis) test was conducted with total of 6 internally trained expert panelists. Each panelist chewed the control gum, or the experimental gum for 6 min. The control gum contained no AITC, and the experimental gums contained 0.01% (100 ppm) of AITC and 0.1% (1000 ppm) of zinc lactate as shown below in Table 5. The panelist evaluated the sweetness intensity, bitterness intensity and off-flavor notes in a 9 point scale (0 - lowest intensity; 9 - highest intensity). Figures 5-7 below show the testing results:

[0075] For the following chewing gum preparations below, gum base was heated to 85°C in a gum mixer. Zinc lactate, sorbitol, intense sweeteners, glycerin and sorbitol syrup were added to the warmed gum base. Allyl-isothiocyanate (AITC) was added to the flavor and stirred well before added to the gum mixer. After addition of the remaining gum ingredients, the gum bolus was sheeted and cut to sticks. Each stick gum weighs 2.7 gram. Table 5 below shows the formulas of experimental gum:
Table 5
IngredientControl GumExperimental Gum AExperimental Gum B
Sorbitol 33.10% 32.95% 31.73%
Gum base 31.00% 31.00% 30.00%
Sorbitol Syrup 33.40% 33.40% 33.00%
Glycerin 0.90% 0.90% 0.90%
Zinc Lactate --- 0.10% 0.10%
Encapsulated high intensity sweetener 0.35% 0.35% 1.1%
High intensity sweetener 0.16% 0.16% 0.16%
Banana flavor 1.00% 1.00% ---
Peppermint oil --- --- 3.00%
AITC (added to flavor oil) --- 0.01% 0.01%
Total 100.0% 100.0% 100.0%







Results



[0076] The data in Figures 5-7 show no significant difference observed for off-flavor (including astringency) and bitterness between the experimental gum-A and the control gum. No significant difference in sweetness intensity was observed as well.

[0077] These results provide evidence that Applicants invention offers a unique, inexpensive, consumer friendly and readily available means for reducing oral malodor associated with VSCs.

c. Breath Freshening Clinical



[0078] A randomized, double-blind clinical study was conducted for evaluation of chewing gum containing zinc lactate and allyl isothiocyanate (AITC). A total of 15 subjects met inclusion and exclusion criteria were recruited and completed the study. Subjects were instructed to refrain from oral hygiene, eating and drinking to the testing site. Each subject exhaled his/her breath to a gas chromatograph to analyze for baseline VSC. Subject was then chewed 1 dose of experimental gum (or control gum) for 12 minutes. Subject exhaled his/her breath to the gas chromatograph immediately after chew, and 60, 120 and 180 minutes. Each test was repeated twice. There were at least two days between treatments. Table 6 below shows the clinical testing results.
Table 6 - Reduction (or increment) of total VSC after treatment
 GumbaseControl gumTest Gum C (0.01% AITC)Test Gum D (0.01% AITC 0.1% ZL)
Baseline 0% 0% 0% 0%
Immediately after chew 15% 46%* 67%* 87%*†
60 min -3% 14% 32%* 56%*†
120 min -44% -23% 29%* 48%*†
180 min -46% -27% 9% 24%*†
(* 2-tail p<0.05 compared with baseline; † 2-tail p<0.05 compared with the control gum)

Results



[0079] Gum base did not show statistically significant reduction of oral malodor, measured by total concentration of VSCs using a gas chromatograph at 60, 120 and 180 min. The gum base actually increased VSCs by 3%, 44% and 46% at 60, 120 and 180 min, respectively.

[0080] Chewing gums containing AITC alone reduced oral malodor by 67%, 32%, 29% and 9% at immediately after chew, 60, 120, and 180 min, respectively.

[0081] Chewing the AITC-ZL gum reduced statistically significant amount of total VSCs by 87%, 56%, 48% and 24% at immediately after chew, 60, 120 and 180 min, respectively.

[0082] Hence, the results show that in combining an isothiocyanate with a zinc salt reduces the level of each if used individually, providing a good tasting, organoleptically pleasing composition which is effective against multiple VSCs, thereby reducing oral malodor. Further, this combination provides breath freshening benefits after consumption for at least 60 minutes.

[0083] In an embodiment, a chewing gum is provided containing less than 0.2% by weight zinc salt, and less than 0.02% by weight isothiocyanate providing breath freshening benefits after consumption to an individual for at least about 2 hours.

[0084] Gum base materials suitable for use in the practice of this invention are well known in the art and include natural or synthetic gum bases or mixtures thereof. The gum base may be incorporated in the chewing gum product at a concentration of about 10 to about 40 wt.% and preferably about 20 to about 35 wt.%.

[0085] Plasticizing/softening agents commonly used in chewing gum compositions are suitable for use in this invention, including gelatin, waxes and mixtures thereof in amounts of about 0.1 to about 5%. The sweetening agent ingredient used in the practice of this invention may be selected from a wide range of materials, and include the same artificial and polyol sweeteners used for the preparation of tablets, beads and lozenges. Polyol sweeteners such as sorbitol and maltitol are present in the chewing gum composition of the invention in amounts of about 40 to about 80 wt.% and preferably about 50 to about 75 wt.%. The artificial sweetener is present in the chewing gum composition of the invention in amounts of about 0.1 to about 2 wt.% and preferably about 0.3 to about 1 wt.%.

[0086] An optional coating may also to be applied to any of oral compositions disclosed herein. Coating material appreciated by those skilled in the art include, but are not limited to waxes, shellac, polyols, carboxymethyl cellulose, polyethylene/malic anhydride copolymer or kappa-carrageenan

[0087] In another embodiment, an oral composition of this invention may further comprise a trigeminal stimulant or sensate including but not limited to menthol and other cooling compounds such as WS-23 and other cooling carboxamide compounds and pungent compounds including but not limiting to capsaicinoids and piperines.

[0088] As shown in further detail below, the invention may be provided in various oral compositions. Accordingly, various embodiments of the invention is illustrated, but not limited by, the following Examples:

EXAMPLE 1



[0089] A chewing gum formulation (designated "Compositions E, F & G") containing isothiocyanates and zinc salts.
IngredientsG
 Weight %
Gum Base 24.34
Sorbitol 58.00
Mannitol 3.00
Lycasin/Glycerin 12.00
Sweetener 0.80
Flavor 1.75
Allyl isothiocyanate (AITC) 0.01
Zinc lactate 0.10

EXAMPLE 2



[0090] This invention is illustrated but not limited by, the dog biscuit formulation (designated "Composition J"). The dog biscuit was prepared according to conventional techniques; and comprises the following ingredients:
IngredientsWeight %
Ground Wheat 30.0
Oats & Bran 17.0
Grits & Seeds 16.5
Gluten 7.5
Sugar 6.0
Fat 5.0
Aromas, Flavors 7.5
Vitamins & Minerals 9.95
Zinc lactate 0.50
Allyl isothiocyanate (AITC) 0.05
IngredientsWeight %
Isomalt 97.83
Xylitol 1.05
High intensity sweetener 0.07
Flavor 0.04
Zinc lactate 1.00
Phenethyl isothiocyanate 0.01

EXAMPLE 4



[0091] This invention is illustrated but not limited by, the dog biscuit formulation (designated "Composition J"). The dog biscuit was prepared according to conventional techniques; and comprises the following ingredients:
IngredientsWeight %
Ground Wheat 30.0
Oats & Bran 17.0
Grits & Seeds 16.5
Gluten 7.5
Sugar 6.0
Fat 5.0
Aromas, Flavors 7.5
Vitamins & Minerals 9.95
Zinc lactate 0.50
Allyl isothiocyanate (AITC) 0.05


[0092] The present invention is not limited to the above embodiments and can be variously modified. The above description of the preferred embodiments, including the Examples, is intended only to acquaint others skilled in the art with the invention, its principles, and its practical application so that others skilled in the art may adapt and apply the invention in its numerous forms, as may be best suited to the requirements of a particular use.

[0093] With reference to the use of the word(s) comprise or comprises or comprising in this entire specification (including the claims below), unless the context requires otherwise, those words are used on the basis and clear understanding that they are to be interpreted inclusively, rather than exclusively, and applicants intend each of those words to be so interpreted in construing this entire specification.


Claims

1. An oral composition being a chewing gum, pet chew or chewy candy, effective to reduce hydrogen sulfide (H2S), methyl mercaptan (CH3SH) or combinations thereof in the oral cavity, said composition comprising:

0.002 to 2 wt.% of zinc lactate; and

0.001 to 5 wt.% of an isothiocyanate;

wherein the weight ratio of zinc lactate : isothiocyanate is 1:1 to 20:1.


 
2. The oral composition of claim 1 wherein the isothiocyanate is selected from the group consisting of sulforaphane (SFN), allyl isothiocyanate (AITC), phenethyl isothiocyanate (PEITC), benzyl isothiocyanate (BITC) and combinations thereof;
 
3. The oral composition of claim 1 wherein the isothiocyanate is selected from the group consisting of 3-morpholinopropyl isothiocyanate, phenylisothiocyanate, and norbornyl isothiocyanate.
 
4. The oral composition of any of claims 1 to 3 wherein the combined amount of zinc lactate and isothiocyanate is less than 0.50% by weight.
 
5. The oral composition of any of claims 1 to 4 wherein the oral composition is uncoated.
 
6. A non-therapeutic method of reducing volatile sulfur compounds in the oral cavity, said compounds being selected from group consisting of hydrogen sulfide (H2S), and methyl mercaptan (CH3SH), said method comprising masticating an oral composition as claimed in any of claims 1 to 5.
 
7. The method of claim 6 wherein the methyl mercaptan (CH3SH) is reduced and wherein the isothiocyanate comprises at least 80% allyl isothiocyanate.
 
8. The method of claim 7 wherein the combination of zinc lactate and allyl isothiocyanate compounds effectively reduce volatile sulfur compounds more than when employed individually.
 
9. The method of claim 7 in which the oral composition contains 0.002 to 2% by weight zinc lactate and 0.001 to 5% by weight allyl isothiocyanate.
 
10. The method of claim 7 wherein the ratio of zinc lactate to allyl isothiocyanate is from about 1:1 to about 20:1.
 
11. The method of claim 6 wherein the isothiocyanate is 3-morpholinopropyl isothiocyanate or phenylisothiocyanate.
 


Ansprüche

1. Orale Rezeptur, bei der es sich um einen Kaugummi, ein Haustier-Kauprodukt oder ein Kaubonbon handelt, und die wirkt, um Schwefelwasserstoff (H2S), Methylmercaptan (CH3SH) oder Verbindungen derselben in der Mundhöhle zu reduzieren, wobei die Rezeptur umfasst:

0,002 bis 2 Gew.-% Zinklaktat; und

0,001 bis 5 Gew.-% eines Isothiocyanats;

wobei das Gewichtsverhältnis Zinklaktat : Isothiocyanat 1:1 bis 20:1 ist.


 
2. Orale Rezeptur nach Anspruch 1, wobei das Isothiocyanat aus der Gruppe ausgewählt ist, die aus Sulforaphan (SFN), Allylisothiocyanat (AITC), Phenethyl-Isothiocyanat (PEITC), Benzyl-Isothiocyanat (BITC) und Verbindungen derselben besteht.
 
3. Orale Rezeptur nach Anspruch 1, wobei das Isothiocyanat aus der Gruppe ausgewählt ist, die aus 3-Morpholinopropyl-Isothiocyanat, Phenylisothiocyanat und Norbornyl-Isothiocyanat besteht.
 
4. Orale Rezeptur nach einem der Ansprüche 1 bis 3, wobei die kombinierte Menge von Zinklaktat und Isothiocyanat weniger als 0,50 Gew.-% beträgt.
 
5. Orale Rezeptur nach einem der Ansprüche 1 bis 4, wobei die orale Rezeptur unbeschichtet ist.
 
6. Nicht-therapeutisches Verfahren zum Reduzieren von volatilen Schwefelverbindungen in der Mundhöhle, wobei die Verbindungen aus der Gruppe ausgewählt sind, die aus Schwefelwasserstoff (H2S) und Methylmercaptan (CH3SH) besteht, wobei das Verfahren ein Mastizieren einer oralen Rezeptur nach einem der Ansprüche 1 bis 5 umfasst.
 
7. Verfahren nach Anspruch 6, wobei das Methylmercaptan (CH3SH) reduziert wird und wobei das Isothiocyanat mindestens 80 % Allylisothiocyanat umfasst.
 
8. Verfahren nach Anspruch 7, wobei die Verbindung aus Zinklaktat und Allylisothiocyanatverbindungen volatile Schwefelverbindungen wirksamer reduziert, als wenn sie einzeln eingesetzt werden.
 
9. Verfahren nach Anspruch 7, bei dem die orale Rezeptur 0,002 bis 2 Gew.-% Zinklaktat und 0,001 bis 5 Gew.-% Allylisothiocyanat enthält.
 
10. Verfahren nach Anspruch 7, wobei das Verhältnis von Zinklaktat zu Allylisothiocyanat von etwa 1:1 bis etwa 20:1 beträgt.
 
11. Verfahren nach Anspruch 6, wobei das Isothiocyanat 3-Morpholinopropyl-Isothiocyanat oder Phenylisothiocyanat ist.
 


Revendications

1. Composition orale étant une gomme à mâcher, un os à mâcher ou un bonbon à mastiquer, efficace pour réduire le sulfure d'hydrogène (H2S), le méthylmercaptan (CH3SH) ou des combinaisons de ceux-ci dans la cavité buccale, ladite composition comprenant :

de 0,002 à 2 % en poids de lactate de zinc ; et

de 0,001 à 5 % en poids d'un isothiocyanate ;

dans laquelle le rapport de poids du lactate de zinc : l'isothiocyanate est de 1:1 à 20:1.


 
2. Composition orale selon la revendication 1 dans laquelle l'isothiocyanate est sélectionné dans le groupe consistant en le sulforaphane (SFN), l'isothiocyanate d'allyle (AITC), l'isothiocyanate de phénéthyle (PEITC), l'isothiocyanate de benzyle (BITC) et des combinaisons de ceux-ci.
 
3. Composition orale selon la revendication 1 dans laquelle l'isothiocyanate est sélectionné dans le groupe consistant en le (3-morpholinopropyl)isothiocyanate, le phénylisothiocyanate et l'isothiocyanate de norbornyle.
 
4. Composition orale selon l'une quelconque des revendications 1 à 3 dans laquelle la quantité combinée de lactate de zinc et d'isothiocyanate est inférieure à 0,50 % en poids.
 
5. Composition orale selon l'une quelconque des revendications 1 à 4 dans laquelle la composition orale est non enrobée.
 
6. Procédé non thérapeutique de réduction de composés soufrés volatils dans la cavité buccale, lesdits composés étant sélectionnés dans le groupe consistant en le sulfure d'hydrogène (H2S) et le méthylmercaptan (CH3SH), ledit procédé comprenant la mastication d'une composition orale telle que revendiquée dans l'une quelconque des revendications 1 à 5.
 
7. Procédé selon la revendication 6 dans lequel le méthylmercaptan (CH3SH) est réduit et dans lequel l'isothiocyanate comprend au moins 80 % d'isothiocyanate d'allyle.
 
8. Procédé selon la revendication 7 dans lequel la combinaison de lactate de zinc et de composés d'isothiocyanate d'allyle réduit de manière efficace les composés soufrés volatils davantage que lorsqu'ils sont employés individuellement.
 
9. Procédé selon la revendication 7 dans lequel la composition orale contient de 0,002 à 2 % en poids de lactate de zinc et de 0,001 à 5 % en poids d'isothiocyanate d'allyle.
 
10. Procédé selon la revendication 7 dans lequel le rapport de lactate de zinc sur l'isothiocyanate d'allyle est d'environ 1:1 à environ 20:1.
 
11. Procédé selon la revendication 6 dans lequel l'isothiocyanate est le (3-morpholinopropyl)isothiocyanate ou le phénylisothiocyanate.
 






Cited references

REFERENCES CITED IN THE DESCRIPTION



This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description